Furosemide in hyaline membrane disease.
In a randomized clinical trial designed to evaluate the effect of diuresis on infants with hyaline membrane disease, seven infants were treated with furosemide (2 mg/kg intravenously) and five received 5% dextrose water in 0.225% sodium chloride (control group). Arterial blood gas analyses performed before and during the six hours after treatment showed no significant difference between control and treated infants. Urine output and urine sodium and calcium loss were significantly increased (P less than .05) in the infants receiving furosemide. The diuresis seemed to have no effect on left atrial size determined echocardiographically, whereas measurements of dynamic skinfold thickness suggested mobilization of subcutaneous water. One infant became seriously dehydrated and hypotensive secondary to a massive diuresis. We concluded that furosemide had a potent diuretic effect in infants with hyaline membrane disease but does not improve cardiorespiratory function acutely. This may be because of failure to mobilize pulmonary interstitial fluid in the time period tested. It may also be possible that the presence of pulmonary interstitial fluid does not play an important role in the impairment of gas exchange in the acute stage of hyaline membrane disease.
D002245:Carbon Dioxide / Q000097:blood; D002986:Clinical Trials as Topic; D005665:Furosemide / Q000494:pharmacology* / Q000627:therapeutic use; D006321:Heart / Q000503:physiopathology; D006801:Humans; D006819:Hyaline Membrane Disease / Q000150:complications / Q000503:physiopathology* / Q000652:urine; D007231:Infant, Newborn; D008168:Lung / Q000503:physiopathology; D010100:Oxygen / Q000097:blood; D010919:Placebos; D011446:Prospective Studies; D011654:Pulmonary Edema / Q000188:drug therapy / Q000209:etiology; D012885:Skinfold Thickness; D014882:Water-Electrolyte Balance / Q000187:drug effects
D010919:Placebos; D002245:Carbon Dioxide; D005665:Furosemide; D010100:Oxygen